` QSOA (Surface Oncology Inc) vs DAX Index Comparison - Alpha Spread

S
QSOA
vs
D
DAX Index

Over the past 12 months, QSOA has underperformed DAX Index, delivering a return of 0% compared to the DAX Index's +22% growth.

Stocks Performance
QSOA vs DAX Index

Loading
QSOA
DAX Index
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
QSOA vs DAX Index

Performance Gap Between QSOA and GDAXI
HIDDEN
Show

Performance By Year
QSOA vs DAX Index

Loading
QSOA
DAX Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Surface Oncology Inc vs Peers

DAX Index
QSOA
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Surface Oncology Inc
Glance View

Market Cap
60.4m EUR
Industry
Biotechnology

Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company. The company is headquartered in Cambridge, Massachusetts and currently employs 67 full-time employees. The company went IPO on 2018-04-19. The firm is developing multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients with cancer. The Company’s pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells through targeting CCR8 (SRF114). In addition, the Company has two partnerships with pharmaceutical companies, including a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562). Its novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies.

QSOA Intrinsic Value
Not Available
Back to Top